Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
Terns Pharmaceuticals (Nasdaq: TERN) announced an upcoming investor educational webinar focused on TERN-701, their investigational next-generation oral BCR-ABL inhibitor for chronic myeloid leukemia (CML). The webinar, scheduled for September 3, 2025 at 4:30 p.m. ET, will precede the anticipated Phase 1 data release in Q4 2025.
The presentation will feature key executives including CEO Amy Burroughs, CMO Emil Kuriakose, and CDO Scott Harris. They will discuss TERN-701's potential best-in-class profile, Phase 1 data benchmarks, and its positioning in the CML treatment landscape. The drug specifically targets the ABL myristoyl pocket and is being developed as an allosteric inhibitor.
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato un webinar informativo per gli investitori incentrato su TERN-701, il loro candidato orale di nuova generazione inibitore di BCR-ABL per la leucemia mieloide cronica (CML). Il webinar, programmato per il 3 settembre 2025 alle 16:30 ET, precederà la prevista pubblicazione dei dati di Fase 1 nel Q4 2025.
La presentazione vedrà la partecipazione di dirigenti chiave, tra cui l’amministratore delegato Amy Burroughs, il direttore medico Emil Kuriakose e il direttore dello sviluppo clinico Scott Harris. Discuteranno del potenziale profilo best-in-class di TERN-701, dei parametri attesi dai dati di Fase 1 e del suo posizionamento nell’ambito terapeutico della CML. Il farmaco è specificamente mirato alla tasca miristoilica di ABL ed è sviluppato come inibitore allosterico.
Terns Pharmaceuticals (Nasdaq: TERN) anunció un seminario web educativo para inversores centrado en TERN-701, su candidato oral de nueva generación inhibidor de BCR-ABL para la leucemia mieloide crónica (LMC). El seminario, programado para el 3 de septiembre de 2025 a las 4:30 p.m. ET, precederá la esperada publicación de los datos de Fase 1 en el cuarto trimestre de 2025.
La presentación contará con ejecutivos clave, incluidos la directora ejecutiva Amy Burroughs, el director médico Emil Kuriakose y el director de desarrollo clínico Scott Harris. Hablarán sobre el posible perfil best-in-class de TERN-701, los criterios de referencia de los datos de Fase 1 y su posicionamiento en el panorama de tratamiento de la LMC. El fármaco se dirige específicamente al bolsillo miristoílico de ABL y se desarrolla como un inhibidor alostérico.
Terns Pharmaceuticals (Nasdaq: TERN)는 만성 골수성 백혈병(CML) 치료를 위한 차세대 경구용 BCR-ABL 억제제 TERN-701에 관한 투자자 교육용 웨비나를 예정하고 있다고 발표했습니다. 웨비나는 2025년 9월 3일 오후 4시 30분(동부시간)에 개최되며, 2025년 4분기 예상되는 1상 데이터 발표에 앞서 진행됩니다.
이번 발표에는 CEO 에이미 버로스(Amy Burroughs), CMO 에밀 쿠리아코스(Emil Kuriakose), CDO 스콧 해리스(Scott Harris) 등 주요 경영진이 참여합니다. 이들은 TERN-701의 잠재적 베스트-인-클래스 프로필, 1상 데이터의 벤치마크, CML 치료 분야에서의 위치를 논의할 예정입니다. 해당 약물은 ABL의 마이리스토일 포켓을 표적으로 하며 알로스테릭(inhibitor) 억제제로 개발되고 있습니다.
Terns Pharmaceuticals (Nasdaq: TERN) a annoncé un webinaire éducatif à destination des investisseurs axé sur TERN-701, son inhibiteur oral BCR-ABL de nouvelle génération en développement pour la leucémie myéloïde chronique (LMC). Le webinaire, prévu le 3 septembre 2025 à 16h30 ET, précédera la publication attendue des données de phase 1 au quatrième trimestre 2025.
La présentation réunira des dirigeants clés, dont la PDG Amy Burroughs, le directeur médical Emil Kuriakose et le directeur du développement clinique Scott Harris. Ils aborderont le profil potentiel « best-in-class » de TERN-701, les points de référence attendus des données de phase 1 et son positionnement dans le paysage thérapeutique de la LMC. Le médicament cible spécifiquement la poche myristoyl d’ABL et est développé en tant qu’inhibiteur allostérique.
Terns Pharmaceuticals (Nasdaq: TERN) gab ein bevorstehendes Investorenschulungs-Webinar zu TERN-701 bekannt, ihrem experimentellen oralen BCR-ABL-Inhibitor der nächsten Generation für chronische myeloische Leukämie (CML). Das Webinar, geplant für 3. September 2025 um 16:30 Uhr ET, findet vor der erwarteten Veröffentlichung der Phase-1-Daten im Q4 2025 statt.
Die Präsentation wird von wichtigen Führungskräften gehalten, darunter CEO Amy Burroughs, CMO Emil Kuriakose und CDO Scott Harris. Sie werden das potenzielle Best-in-Class-Profil von TERN-701, erwartete Benchmarks der Phase-1-Daten und die Positionierung in der CML-Therapielandschaft erörtern. Das Medikament zielt spezifisch auf die Myristoyl-Tasche von ABL ab und wird als allosterischer Inhibitor entwickelt.
- None.
- None.
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET
FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data release expected in fourth quarter of 2025. The webinar will review TERN-701’s potential best-in-class profile, relevant benchmarks for upcoming Phase 1 data and positioning in an evolving treatment landscape for chronic myeloid leukemia (CML).
TERN-701 is an investigational next-generation oral, allosteric BCR-ABL inhibitor specifically targeting the ABL myristoyl pocket that is being evaluated for the treatment of CML.
The webinar will be led by Amy Burroughs, chief executive officer, Emil Kuriakose, M.D., chief medical officer and Scott Harris, chief development officer, of Terns. Event details are as follows:
TERN-701: Investor Educational Webinar
Date and Time: September 3, 2025 at 4:30 p.m. ET
Webinar Link: Register
A webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website.
About TERN-701 and CARDINAL Phase 1 Clinical Trial
TERN-701 is currently being evaluated in the CARDINAL trial (NCT06163430), a global multi-center dose escalation and dose-expansion Phase 1 clinical trial to assess safety, tolerability and efficacy in patients with previously treated chronic phase (CP) CML. The dose escalation portion of the Phase 1 CARDINAL study completed in January 2025 with no dose limiting toxicities (DLTs) observed up to the maximum dose of 500 mg QD. Terns initiated the dose expansion portion study in April 2025 with patients randomized to one of two dose cohorts (320 mg or 500 mg QD) with up to 40 patients per arm. Terns plans to report efficacy and safety data from the Phase 1 CARDINAL trial in the fourth quarter of 2025, including 6-month major molecular response achievement rate.
Previously announced positive interim data from the dose escalation portion of the trial demonstrated compelling molecular responses starting at the lowest dose in heavily pre-treated CML patients with high baseline BCR-ABL transcript levels. It also showed an encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations or dose reductions across all dose escalation cohorts.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the Company within the meaning of the federal securities laws. Forward-looking statements include statements related to or in connection with expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners, including with respect to the CARDINAL and FALCON trials, as well as enabling and non-clinical studies of the TERN-800 Series and TERN-501; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company’s small-molecule product candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company’s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company’s clinical trials; the Company’s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company’s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company’s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the process, timing or potential to establish a strategic partnership or similar arrangement for future development and/or potential commercialization of any of its product candidates; the potential commercialization of the Company’s product candidates; and the Company’s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “develop,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioning,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
When will Terns Pharmaceuticals (TERN) release Phase 1 data for TERN-701?
What is TERN-701 being developed to treat?
When is the Terns Pharmaceuticals TERN-701 investor webinar?
Who will present at the Terns Pharmaceuticals TERN-701 webinar?
How can investors access the Terns Pharmaceuticals TERN-701 webinar?
